Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators. Dimopoulos MA, et al. Among authors: sandhu i. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Online ahead of print. N Engl J Med. 2024. PMID: 39652675
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. Among authors: sandhu i. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.
Oriol A, Hájek R, Spicka I, Sandhu I, Cohen YC, Gatt ME, Mariz J, Cavo M, Berdeja J, Jin K, Bar M, Das P, Motte-Mohs R, Wang Y, Perumal D, Costa LJ. Oriol A, et al. Among authors: sandhu i. Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):703-714. doi: 10.1016/j.clml.2024.05.014. Epub 2024 May 19. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38849283 Clinical Trial.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Moreau P, et al. Among authors: sandhu i. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. N Engl J Med. 2016. PMID: 27119237 Free article. Clinical Trial.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study.
Visram A, Chan KK, Seow H, Pond G, Gayowsky A, Mohyuddin GR, McCurdy A, Sandhu I, Venner C, Lancman G, Balitsky A, Kouroukis T, Bruins R, Kumar S, Fonseca R, Mian H. Visram A, et al. Among authors: sandhu i. Haematologica. 2024 Aug 22. doi: 10.3324/haematol.2024.285768. Online ahead of print. Haematologica. 2024. PMID: 39219457 Free article.
Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS.
Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis RM, Carson R, Hofmeister CC. Landgren CO, et al. Among authors: sandhu i. Blood. 2024 Dec 9:blood.2024025897. doi: 10.1182/blood.2024025897. Online ahead of print. Blood. 2024. PMID: 39652826
Defects in meiosis I contribute to the genesis of androgenetic hydatidiform moles.
Rezaei M, Liang M, Yalcin Z, Martin JH, Kazemi P, Bareke E, Ge ZJ, Fardaei M, Benadiva C, Hemida R, Hassan A, Maher GJ, Abdalla E, Buckett W, Bolze PA, Sandhu I, Duman O, Agrawal S, Qian J, Vallian Broojeni J, Bhati L, Miron P, Allias F, Selim A, Fisher RA, Seckl MJ, Sauthier P, Touitou I, Tan SL, Majewski J, Taketo T, Slim R. Rezaei M, et al. Among authors: sandhu i. J Clin Invest. 2024 Nov 15;134(22):e170669. doi: 10.1172/JCI170669. J Clin Invest. 2024. PMID: 39545410 Free PMC article.
81 results